JPRN-jRCTs031180405
Completed
未知
Safety evaluation study about rituximab therapy for refractory pemphigus
Funakoshi Takeru0 sites20 target enrollmentMarch 22, 2019
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Funakoshi Takeru
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Patient diagnosed as pemphigus and relapse disease taking corticosteroids more than PSL 10mg/day.
- •2\) PDAI\>\=1
- •3\) Greater than or equal to 20 years of age and younger than or equal to 80 years of age.
- •4\) Able to understand and sign the Informed Consent Document.
Exclusion Criteria
- •1\) Women who may possibly be pregnant or pregnant and men who plan to impregnate a woman.
- •2\) Allergy to humanized monoclonal antibody and/or murine monoclonal antibody, murine derived component.
- •3\) Active major medical illnesses.
- •4\) Active infections.
- •5\) Past history of infection within 8weeks.
- •6\) Past history of taking antibiotics (oral ; within 2weeks, infusion ; 8weeks).
- •7\) Past history of bacteremia within 1 year.
- •8\) Past history of deep tissue infections and/or abscess.
- •9\) chronic and/or recurrent infections.
- •10\) Past history ofPatients who have or had malignancies.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Safety evaluation study about rituximab therapy for refractory pemphiguspemphigusJPRN-UMIN000026004Keio University, School of Medicine20
Completed
Not Applicable
A study of the efficacy and safety to rituximab in treating adult onset refractory nephrotic syndromeRefractory nephrotic syndromeJPRN-UMIN000021143Fujita Health University School of Medicine, Department of Nephrology10
Completed
Phase 2
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients with Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical TrialChronic Inflammatory Demyelinating PolyneuropathyJPRN-UMIN000035753agoya University Hospital27
Completed
Phase 2
RECIPE TrialJPRN-jRCT2041180037Iijima Masahiro25
Unknown
Phase 2
Clinical study for effectiveness of rituximab for acquired coagulopathyacquired coagulopathyJPRN-UMIN000024612Gunma University10